Medovate commercialises innovative medical technologies created within the NHS. As the fifth largest employer in the world, the NHS plays a significant role in creating medical innovations that address unmet clinical needs, potentially creating revenue and impact. Medovate provides technical, management and financial support to develop medical devices through clinical trials, regulatory approval and commercialisation.
The first product Medovate is launching is SAFIRA (safer injection for regional anaesthesia), which enables a single operator to conduct a regional block at a safer pressure, reducing the risk of nerve damage and improving patient safety.
Alan Finnerty is primarily responsible for R&D at Medovate. He also leads on quality assurance, clinical trials, regulatory approvals and manufacturing.
Medovate has a portfolio of medical technologies covering anaesthesia, critical care, airway and surgery. The company has recently taken on development of a technology that has been awarded £1.3 million by the NIHR with Cambridge University Hospitals NHS Foundation Trust – Addenbrooke’s Hospital. The technology is called Endovac, an innovative negative pressure wound therapy device for the treatment of upper gastro-intestinal leaks. Early indications are that it will dramatically improve patient survival rates.
